FEB Frankfurt, Germany
Attana's CEO, Teodor Aastrup will attend this event and participate in a panel discussion focusing on : What does the future look like for antibody and protein engineering?
Professor Andreas Plückthun, Professor of Biochemistry, University of Zurich
Dr William Strohl, Vice President, Biologics Research, Johnson & Johnson
Dr David Wenyan Shen, Executive Director, Merck Biologics
The event has been designed by people from companies like Genentech, MedImmune, Roche, Abbott, Johnson & Johnson, Biogen Idec, Merck, UCB Celltech, Pfizer and many other big pharmaceutical companies and innovative biotechs.